BLEOMYCIN SULFATE

Post-LOE

bleomycin sulfate

Entera Bio

ANDAINJECTIONINJECTABLE

Approved

Jun 1996

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

BLEOMYCIN SULFATE (bleomycin sulfate) by Entera Bio is clinical pharmacology: mechanism of action although the exact mechanism of action of bleomycin is unknown, available evidence indicates that the main mode of action is the inhibition of dna synthesis with some evidence of lesser inhibition of rna and protein synthesis. Approved for lymphoma, lymphoma. First approved in 1996.

Drug data last refreshed 1w ago

Mechanism of Action

CLINICAL PHARMACOLOGY: Mechanism of Action Although the exact mechanism of action of bleomycin is unknown, available evidence indicates that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis. Bleomycin is known to cause…

Worked on BLEOMYCIN SULFATE at Entera Bio? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

BLEOMYCIN SULFATE

Mechanism of Action

Indications (1)